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Background: Polymorphisms in the excision repair cross-complimentary group 1 (ERCC1) gene have been involved in
the prognosis of various cancers. In the present study, we evaluated the prognostic role of the two most common
ERCC1 polymorphisms in patients with T4 breast cancer receiving platinum-based chemotherapy.
Methods: A total of 47 patients with T4 breast cancer undergoing treatment with a platinum-based regimen were
collected and followed up (median 159 months; range, 42–239 months). ERCC1 C8092A (rs3212986) and T19007C
(rs11615) polymorphisms were genotyped, using an automated sequencing approach. The same series was
screened for BRCA1/2 mutations by DHPLC analysis and DNA sequencing.
Results: Among the tested patients, 16 (34%) and 25 (53%) presented the 8092A (homo-zygosity A/A or
heterozygosity A/C) and the 19007C (homozygosity C/C or heterozygosity C/T) genotypes, respectively. The 8092A
and 19007C genotypes in ERCC1 were significantly associated with overall survival in T4 breast cancer patients
treated with chemotherapy containing platinum (p-values = 0.036 and 0.004, respectively). Univariate and
multivariate Cox regression analyses showed that combination of 8092A and 19007C genotypes acts as a significant
prognostic factor in women with T4 breast cancer receiving platinum-based chemotherapy (p-values = 0.022 and
0.049, respectively). Two (4.3%) out of 47 cases were found to carry BRCA1/2 mutations; they presented the highest
overall survival rates into the series.
Conclusions: The ERCC1 8092A and 19007C genotypes or their combination may predict a favorable prognosis in
T4 breast cancer patients undergoing a platinum-based treatment. Further large-scale, prospective studies are
needed to validate our findings.
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Breast cancer remains the most frequent tumor and the
leading cause of cancer-related death among the female
population worldwide [1].
Locally advanced breast cancer (LABC) represents a
heterogeneous group of diseases associated with a poor
prognosis. According to the International Union Against
Cancer (UICC)/American Joint Committee on Cancer
(AJCC) TNM staging system, primary breast cancers with* Correspondence: gpalmieri@yahoo.com
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unless otherwise stated.extension to the skin, with or without lymph node involve-
ment, and without distant metastases (T4 N0-2 M0), may
be included in stage III and considered as LABC [2].
Overall, patients with LABC - including cases present-
ing an inflammatory disease and, mostly, those carrying
a triple-negative breast cancer - are particularly respon-
sive to DNA-damaging agents such as platinum com-
pounds; for this reason, platinum-based chemotherapy is
frequently used as neoadjuvant treatment in such dis-
ease types [3-6]. The cytotoxic effect of platinum drugs
is ascribed to the formation of bulky platinum-DNA ad-
ducts, which block replication and transcription through
inter-strand cross-link of the two DNA strands, leadingal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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removed, with subsequent repair of the inter-strand
cross-links in DNA, by factors of the nucleotide excision
repair (NER) pathway [7]. Recent published data have
revealed that single nucleotide polymorphisms (SNPs) in
DNA repair genes may represent an underlying molecu-
lar mechanism that explains inter-individual variation in
DNA repair capacity [7].
The excision repair cross-complementing 1 (ERCC1)
is one of the key effector of the NER pathway. This en-
zyme acts as a DNA damage repair gene, which is essen-
tial for the removal of platinum-DNA adducts as well as
for recognition and correction of DNA damage [8].
Functional variants in genes involved in the DNA repair
pathway may be important determinants of platinum
response [9]. Therefore, ERCC1 mRNA and protein ex-
pression level or ERCC1 gene polymorphisms may be used
to predict the outcome in patients receiving platinum-
based chemotherapy [10,11].
C8092A (rs3212986) and T19007C (rs11615) are two
common polymorphisms in ERCC1 gene. The C8092A
polymorphism is located in the 3′untranslated region of
the gene and may affect ERCC1 messenger RNA stabil-
ity. The synonymous T19007C polymorphism at codon
118 (Asn118Asn) converting a common codon usage
(AAC) to an infrequent one (AAT), both coding for as-
paragine, has been proposed to impair ERCC1 transla-
tion and to affect the response to chemotherapy [12].
In recent years, many studies focused on the associ-
ation between clinical behavior of different types of can-
cer and specific SNPs in genes involved in DNA repair,
including genes of the NER pathway. Although contro-
versial results have been reported for association be-
tween polymorphisms of ERCC1 and cancer outcome
(see below), increasing and more consistent evidence
suggest a relationship between the level of ERCC1 ex-
pression and the response to chemotherapy. Higher
mRNA levels of ERCC1 are associated with lack of plat-
inum response in advanced lung [13,14], ovarian [15],
bladder [16], and gastrointestinal [17-19] cancers. Con-
sequently, lower ERCC1 mRNA levels have been found
consistently associated with an improved tumor re-
sponse using platinum-containing compounds [8,14,17].
Polymorphisms in ERCC1 gene have been studied ex-
tensively, with controversial results. A study indicates
that the codon 118 C > T polymorphism was not associ-
ated with clinical outcome in women with stage III ovar-
ian cancer, whereas the C8092A polymorphism was an
independent predictor of progression-free survival and
overall survival (OS) in the same series of patients [20].
In contrast to this findings, additional reports indicated
that the C/C genotype at codon 118 of ERCC1 expres-
sion may predict the response to platinum in either the
same type of ovarian cancer [15] or other malignancies[12,21]. Overall, the T19007C polymorphism showed a
controversial association with clinical outcome (in terms
of either tumor response or OS) among different types of
cancers [22-24]. The C8092A polymorphism was instead
associated with a more favorable outcome in head and
neck squamous cell carcinoma and advanced non small
cell lung cancer patients [25,26]. Finally, the accumulated
evidence provided by a meta-analysis of the literature
clearly indicated that ERCC1 T19007C and C8092A poly-
morphisms might not act as risk factors for cancer [27].
There are differences in survival among patients who
begin treatment in a similar disease status and genetic
factors may influence the effectiveness of therapy. For
this reason the availability of new biomarkers that can
accurately predict the prognosis and patient response to
the treatment is a central issue to improve therapeutic
strategies.
The aim of the present study was to investigate whether
the ERCC1 19007C > T and 8092C >A polymorphisms
may influence the clinical outcome in response to treat-
ment with platinum within a well-characterized cohort of
patients with T4 breast carcinoma and long follow-up
evaluation. Since germline mutations in BRCA1 and, to a
less extent, BRCA2 genes have been found in a variable
proportion (ranging from 10% to 30%) of patients with
LABC or, mostly, triple-negative breast cancer [28], and
such gene dysfunctions seem to be associated with prog-
nosis [29], we also evaluated the prevalence of BRCA1-2
mutations in our series.
Materials and methods
Samples
Germline DNA samples of 47 consecutive patients with
T4 breast cancer [12 (26%) of them classified as inflam-
matory breast cancer (T4d-IBC)] were included into the
study. Cases were enrolled between 1995 and 2004, and
observed up to July 2013 for an overall median of
161 months (range, 13–242 months). Patients were
assessed by physical examination and mammography,
confirmed via core-needle biopsy. All patients completed
a treatment plan including neoadjuvant platinum-based
chemotherapy, surgery, radiation therapy, adjuvant
chemotherapy, and hormone therapy, when indicated (see
below). All patients were of Sardinian origin; the median
age at diagnosis was 51 years (range 33–67 years). Patients’
characteristics are summarized in Table 1.
The study was approved by the Review Board at the
University of Cagliari (Prot. 102/1996). A written in-
formed consent was obtained for using tissue specimens
in molecular analyses.
Treatment plan
All 47 patients were treated with primary chemotherapy
using PEV [cisplatin, epirubicin, vinorelbine; N = 42 (89%)]
Table 1 Patients’ characteristics and clinical features
Characteristics Patients (N = 47) %
Age (year)




Ductal carcinoma 29 62













ER positive/ER negative 23/24 49/51
PR positive/PR negative 16/31 34/66
HER2 status
HER-2 positive 13 28





Ki67 positive 24 51
Ki67 negative 23 49
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After completing the neoadjuvant chemotherapy, pa-
tients underwent breast-conserving surgery (17/47; 36%)
or radical mastectomy (30/47; 64%). Postoperative adju-
vant chemotherapy consisted of six cycles of CMF (cyclo-
phosphamide, methotrexate, fluorouracil). Locoregional
radiotherapy was performed during the fourth course of
CMF. After completing adjuvant chemotherapy, patients
with hormone receptor-positive tumours received tam-
oxifen for 5 years.
Clinical evaluations were performed every 3 months
for 2 years and every 6 months thereafter. Instrumental
examinations (e.g., mammography, liver ultrasound,
chest X-ray, bone scan, and echocardiogram) were per-
formed every 6 months for the first 2 years, and every
12 months thereafter.Genetic analysis
Genomic DNA from all patients was isolated from per-
ipheral blood nucleated cells, using standard methods,
and then screened for the C > A and C > T polymor-
phisms at positions 8092 and 19007, respectively, of the
ERCC1 gene, using an automated direct sequencing ap-
proach. Primers for polymerase chain reaction (PCR) as-
says and protocols for PCR-based amplification have
been previously described [30].
The entire coding sequences and intron-exon bound-
aries of the BRCA1 and BRCA2 genes were screened for
germline mutations among all patients from our series.
Mutation analysis was performed by denaturing high-
performance liquid chromatography (DHPLC), followed
by automated sequencing, as we previously reported
[31,32]. Briefly, DHPLC analysis was carried out with the
Wave® nucleic acid fragment analysis system (Transge-
nomic, Santa Clara, CA). Suspected variants are visual-
ized as a characteristic pattern of peaks corresponding
to the mixture of homo- and heteroduplex formed when
wild-type and mutant DNA are hybridized. Abnormal
PCR products identified by DHPLC analysis were dir-
ectly sequenced using an automated fluorescence-cycle
sequencer (ABIPRISM 3130, Life Technologies/Thermo-
Fisher Scientific, Waltham, MA, USA).
Statistical analysis
Odds ratios of carrying the ERCC1 19007C > T and
8092C > A polymorphisms were estimated by the logistic
regression model and reported with 95% confidence
interval (95% CI). Analyses were performed with the
statistical package SPSS/7.5 for Windows.
Results
Patient characteristics and treatments
Forty-seven patients with diagnosis of T4 breast carcin-
oma (T4-N0/2-M0, according to the TNM classification
by Sobin et al. [33]) were included into the study. Con-
sidering the disease staging system [33], all cases from
our series were classified with the highest stage of non-
metastatic disease (Stage IIIB). Among them, 19 (40%)
patients presented the subtype of triple-negative breast
cancer, with the characteristics of estrogen receptor (ER)
negative, progesterone receptor (PR) negative, and human
epidermal growth factor receptor-2 (HER-2) negative
(Table 1). All the patients received platinum-based chemo-
therapy as the neoadjuvant treatment: nearly all of them
(89%; see Methods) received PEV treatment. After surgery,
adjuvant treatment included CMF chemotherapy for six
cycles and locoregional radiotherapy (see Methods).
C9082A and T19007C polymorphisms in ERCC1
Genomic DNA samples were extracted from periph-
eral blood mononuclear cells and single nucleotide
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(rs11615), in the ERCC1 gene were analyzed using an
automated sequencing approach.
For C8092A, 16 (34%) patients presented the A geno-
type (3 AA, 13 AC), whereas 31 (66%) cases presented the
C genotype (CC). For T19007C, the C (12 CC, 13 CT)
and the T (TT) genotypes were found in 25 (53%) and 22
(47%) patients, respectively. Both distributions were in
Hardy-Weinberg equilibrium. Considering the two poly-
morphisms the distribution of AC, AT, CC and CT geno-
types was 25.5%, 8.5%, 28%, and 38%, respectively.
BRCA mutation analysis
The germline DNA samples from the T4 breast carcin-
oma patients of the present study was analyzed for mu-
tations in both the BRCA1 and BRCA2 genes, as
previously described [31,32]. Among the 47 cases of the
series, two germline coding region mutations of known
functional significance in either BRCA1 or BRCA2 were
detected in two (4.3%) patients. Both mutations, BRCA1
(2CA) 916delTT and BRCA2 3951del3insAT, were ab-
sent in normal genomic DNA from 103 unrelated
healthy individuals (corresponding to 206 control chro-
mosomes) and were classified as disease-causing variants
due to their predicted effects on proteins.
Survival analysis
As of July 2013, 18 (38%) patients have died due to dis-
ease, with the median overall survival of the whole sam-
ple being 108 months and the median follow-up of live
patients of 153 months.
According to the C8092A polymorphism status, the
median OS was significantly higher for patients carrying
the A (AA +AC) genotype as compared to those with
the C (CC) genotype (123.5 vs.101.6 months; p = 0.036).
Analogously, a significantly strong association between
the T19007C polymorphism and overall survival was ob-
served; the median OS was 131 months for carriers of
the C (CC + CT) genotypes and 66.5 months for TT ho-
mozygotes (p = 0.004) (Table 2A). When the combinationTable 2 Logistic regression analysis for overall survival
and ERCC1 polymorphisms
A
Odds ratio 95% CI lower 95% CI upper p-value
C8092A 1.957 1.276 5.675 0.036
T19007C 3.875 1.865 18.851 0.004
B
Odds ratio 95% CI lower 95% CI upper p-value
C8092 + T19007 2.479 0.538 11.421 0.244
8092A + 19007C 5.609 1.278 24.622 0.022
Single (A) or combined (B) ERCC1 genotypes have been considered for statistical
analysis. Significant associations are in bold. CI, confidence interval.of both ERCC1 polymorphisms were included in univar-
iate analysis, carriers of the combined 8092A/19007C
genotype presented an overall survival significantly lon-
ger than that of patients carrying the combined C8092/
T19007 genotype (143.5 vs. 91.7 months; p-value = 0.022)
(Table 2B). No association between T19007 or C8092A
ERCC1 polymorphisms and age at diagnosis, tumor
grade, histology, menopausal condition was detected (not
shown).
Using the Kaplan-Meier method, survival curves indi-
cated that patients carrying either 8092A or 19007C geno-
types presented a statistically-significant better overall
survival in comparison with those carrying the remaining
other genotypes (p < 0.001 for both 8092A and 19007C
genotypes; Figure 1).
Using the Cox model adjusted according to age at diag-
nosis for a multivariate analysis, pathological response to
primary chemotherapy and both two ERCC1 polymor-
phisms remained the only parameters with a significant
impact on prognosis in our series of breast cancer pa-
tients; no other association with overall survival was ob-
served for the remaining variables (Table 3A). Again, the
combined 8092A/19007C genotype remained a statisti-
cally independent factor predicting a more favourable
prognosis in multivariate logistic regression (p = 0.049)
(Table 3B).
Finally, it is worthy to notice that the two patients
who carried a BRCA1 or BRCA2 germline mutation pre-
sented the highest overall survival rates of the series
(238 and 195 months, respectively).
Discussion
In this study, two single nucleotide polymorphisms,
C8092A and T19007C, in ERCC1 gene were retrospect-
ively evaluated for their association with the clinical be-
havior in a group of T4 breast carcinoma patients of
Sardinian origin, receiving platinum-based chemother-
apy. We have demonstrated that two genotypes within
such polymorphisms have a role as independent prog-
nostic factors for a more favorable clinical outcome in
this subset of patients.
In breast cancer, the choice of cytotoxic chemotherapy
is generally based on tumor extent and disease features.
Identification of surrogate markers as potential predict-
ive factors will be useful to improve the clinical manage-
ment of breast cancer patients (i.e., to identify which
subset of patients is expected to show either a response
or a lack of response to a particular therapy). Various
attempts have been made to improve the survival of pa-
tients with T4 breast carcinoma, for instance, discover-
ing novel predictive biomarkers to identify patients who
may really benefit from platinum-based chemotherapy.
Platinum agents such as cisplatin and carboplatin are
DNA-damaging agents with activity in breast cancer,
Figure 1 Kaplan-Meier curves for ERCC1 C8092A (A) and T19007C (B) polymorphisms in T4 breast cancer patients.
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neoadjuvant strategies for the treatment of locally ad-
vanced breast cancer (LABC), the utility of platinum
agents in addition to standard chemotherapy is yet to be
completely clarified. Therefore, identification of factors
relevant to better predict the clinical outcome in re-
sponse to platinum agents may be helpful in achieving
an absolute advantage for the management of the LABC
disease.
ERCC1 (excision repair cross complementation group
1) can recognize and correct DNA damage through a
DNA strand incision and homologous recombination
mechanisms [8,30]. High ERCC1 expression has been
demonstrated to be associated with resistance to
platinum-based chemotherapy and worse prognosis in
cancer patients [20,37,38]. To this aim, we here assessedthat the ERCC1 gene polymorphisms may play an analo-
gous clinical role as predictive and prognostic factor
among patients with T4 breast cancer receiving platinum-
based therapy.
Several clinical studies have explored the role of
ERCC1 as a marker for platinum sensitivity in cancer
patients. For example, various studies have focused on
the relationship between ERCC1 polymorphisms and
prognosis for the treatment with platinum agents in
colorectal cancer patients. Sequence variations in ERCC1
gene may indeed alter the DNA repair capacity, making
biologically plausible to assume that polymorphisms of
this gene might have functional significance in cancer.
In our study, the ERCC1 polymorphisms were deter-
mined using an automated sequencing method. For
C8092A polymorphism, the A genotype was significantly
Table 3 Cox proportional hazard model for multivariate analysis of different parameters
A
Characteristics p-value Odds ratio 95% CI lower 95% CI upper
Menopausal status 0.176 0.854 0.177 1.465
Age at diagnosis 0.283 0.916 0.110 1.906
ER 0.454 0.809 0.191 2.233
HER-2 0.483 0.971 0.117 2.602
Triple negative status 0.128 1.006 0.213 2.834
Tumor grading 0.982 0.968 0.194 4.075
Lymph node (N+) 0.644 0.873 0.125 3.614
Pathological response to primary chemotherapy 0.043 5.274 1.388 26.173
8092A 0.048 2.690 1.091 9.053
19007C 0.031 4.177 1.226 23.131
B
Characteristics p-value Odds ratio 95% CI lower 95% CI upper
C8092 + T19007 0.430 1.266 0.334 3.231
8092A + 19007C 0.049 4.377 1.031 23.112
ER 0.332 0.793 0.143 2.655
PR 0.459 1.127 0.178 4.117
HER-2 0.139 0.699 0.166 1.223
Ki67 0.073 0.222 0.053 1.081
Pathological response to primary chemotherapy 0.051 0.565 0.136 1.377
Single (A) or combined (B) ERCC1 genotypes have been considered for statistical analysis. Significant associations are in bold. CI, confidence interval.
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tients treated with chemotherapy containing platinum
compounds (OR 1.957, 95%CI 1.276- 5.675; p value =
0.036). Analogously, the C genotype of T19007C poly-
morphism was significantly associated with overall sur-
vival in the same series (OR 3.875, 95%CI 1.865-18.851;
p-value = 0.004). Univariate and multivariate Cox regres-
sion analyses showed that the combination of the 8092A
and 19007C genotypes acts as an independent prognos-
tic factor in this group of T4 breast cancer patients re-
ceiving platinum-based chemotherapy (p-values = 0.022
and 0.049, respectively).
The precise mechanism by which the C8092A poly-
morphism is positively associated with a favorable prog-
nosis remains indeterminate, as there are no direct
functional data available for this polymorphism. Since
the SNP is located at the 3′untranslated region (3′-
UTR) which can be controlled by regulatory proteins
and micro-RNAs, the C8092A polymorphism in the 3′-
UTR region could however affect the stability and, thus,
translation rates of the corresponding mRNA, finally in-
fluencing the expression levels of the ERCC1 protein
into the cells. On the other side, the synonymous
T19007C polymorphism at codon 118 (Asn118Asn) is a
common silent substitution, and the exact function of
Asn118Asn has not been clarified yet. Again, it couldalso affect the stability of mRNA or influence the rates
of translation by converting a high usage codon to a low
usage one. Alternatively, it could be biologically plausible
that this correlation may be mediated by linkage disequi-
librium with other potentially functional single-nucleotide
polymorphisms.
The entire group of 47 patients was then screened for
germline mutations in BRCA1/2 genes and, of note, two
(4.3%) carriers of BRCA1/2 mutations presented the
highest rates of overall survival within the series. No
statistical analysis was carried out due to such a limited
number of BRCA-mutated cases. The lack of functional
BRCA (mainly, BRCA1) can lead to increased sensitivity
of the tumor cells to molecular damage, demonstrating
that BRCA mutations represent a predictive marker of
response to DNA-damaging chemotherapies [39-41].
Certainly, the reduced ability to repair damaged DNA
along with the impairment of the function of the ERCC1
protein, due to the presence of the combined 8092A and
19007C genotypes, may have contributed to determine
the longest overall survival in such a limited subset of
patients from our series.
Several limitations of this study should be addressed.
Firstly, the sample size may limit the statistical power of
our study (findings need further replication in a larger
patients’ collection); next, the belonging of cases to a
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may interfere with observed associations in multifactorial
diseases; extension of the study in other geographical areas
with general, genetically-heterogeneous populations is also
recommended). However, to our knowledge, this is the
first study clearly demonstrating that polymorphisms in
ERCC1 gene are significantly associated with overall sur-
vival in patients with T4 breast cancer receiving platinum-
based treatment. Overall, this seems to suggest that such
sequence variations could be considered as novel prognos-
tic biomarkers for the management of the T4 breast can-
cer patients.
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